Simple Summary
This is a review article detailing available evidence on the use of CAR-T cell therapy and bispecific antibodies (BsAbs) in non-Hodgkin’s lymphoma—specifically diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The review hopes to detail where CAR T-cell therapy and BsAbs fit in our current treatment paradigm, as well as foreshadow what is to come in the near future.
Abstract
Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies. These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.